Treating IIA/B seminoma with combination carboplatin and radiotherapy

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 2101-2102

  Gilbert, Duncan C ^a   VanAs, Nicholas J ^a   Beesley, Sharon ^b   Bloomfield, David ^c   Money Kyrle, Julian ^d   Norman, Andy ^a   Dearnaley, David ^a   Horwich, Alan ^a   Huddart, Robert A ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Kent Cancer Centre   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; SEMINOMA; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 65349122437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.5269     Document Type: Letter

References (10)

1. Garcia-del-Muro X, Maroto P, Guma J, et al: Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish Germ Cell Cancer Group study. J Clin Oncol 26:5416- 5421, 2008
2. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513- 1523, 2003
3. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
4. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006
5. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatmentspecific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
6. Zwahlen DR, Martin JM, Millar JL, et al: Effect of Radiotherapy Volume and Dose on Secondary Cancer Risk in Stage I Testicular Seminoma. Int J Radiat Oncol Biol Phys 70:853-858, 2008
7. von der Maase H: Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? Radiother Oncol 59:1-3, 2001
8. Patterson H, Norman AR, Mitra SS, et al: Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: Comparison with radiotherapy treatment alone. Radiother Oncol 59:5-11, 2001
9. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 366:293-300, 2005
10. Powles T, Robinson D, Shamash J, et al: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19:443-447, 2008